Avalon Pharmaceuticals Inc.
This article was originally published in Start Up
Avalon Pharmaceuticals Inc. hopes to harness the explosion of target information to identify promising drugs without having to rely first on finding new targets. It is employing its target-independent platform to look at the activities of compounds much earlier in the discovery process than conventional screening methods.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.